Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03289039 · ClinicalTrials.gov registry record · Phase 2
Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT03289039 is a Phase 2 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 21 participants.
The verdict
NCT03289039, a Phase 2 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This research study is studying a drug called Neratinib with and without Fulvestrant as possible treatments for HER2-positive breast cancer . The interventions involved in this study are: * Neratinib and Fulvestrant * Neratinib alone
Interventions
- DRUG Neratinib
- DRUG Fulvestrant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-10-25 |
| Est. Completion | 2021-07-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03289039
The ClinicalTrials.gov registry entry for NCT03289039 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Neratinib is the first listed.
NCT03289039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03289039 about?
NCT03289039 is a clinical study titled "Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer". This research study is studying a drug called Neratinib with and without Fulvestrant as possible treatments for HER2-positive breast cancer . The interventions involved in this study are: * Neratinib and Fulvestrant * Neratinib alone
What is the current status of trial NCT03289039?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2017-10-25. Estimated completion is 2021-07-20.
What interventions are being tested in trial NCT03289039?
The interventions under investigation include: Neratinib (DRUG), Fulvestrant (DRUG).
Who is sponsoring clinical trial NCT03289039?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.